Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer

NCT07558733 is registered in ClinicalTrials.gov with Faeth Therapeutics as lead sponsor.

NCT NCT07558733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07558733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer
Lead sponsor
Faeth Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 22, 2026
Completion date
May 31, 2033
Enrollment
32 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hr+ her2- breast cancer